Nexalin Technology Inc (NXL) — Titan Protect Analysis

NXL

Nexalin Technology Inc

Healthcare · ·

$0.52

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$11M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-1.68

Based on estimated future earnings — lower means cheaper

Rev Growth

-63.6%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-319.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$2.00

+282% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 1 analysts covering this stock

About Nexalin Technology Inc

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic br

https://www.nexalin.com

Country: United States Employees: 8 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.649

Good returns relative to risk taken

Kelly Fraction

0.0337

Modest edge detected — smaller position warranted

Calmar Ratio

-0.122

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-11.3%

Historical annualised return based on price data

Max Drawdown

-92.6%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$2.00

74% below the year high

52W Low

$0.31

72% above the year low

Avg Volume

801,582

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.5

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.46

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

82.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-14,180.0%

Profit from core operations before interest and tax

Free Cash Flow

$-2,092,449

Negative — the business is spending more than it generates

Revenue (TTM)

$275,582

Total revenue over the last 12 months

Net Income

$-8,330,681

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$2.00

Target Median

$2.00

Target Low

$2.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go